Interdisciplinary, internet-based trans health care (i²TransHealth): study protocol for a randomised controlled trial. Issue 2 (1st February 2022)

• Record Type: Journal Article
• Authors: Nieder, Timo O.; Renner, Janis; Zapf, Antonia; Sehner, Susanne; Hot, Amra; König, Hans-Helmut; Dams, Judith; Grochtdreis, Thomas; Briken, Peer; Dekker, Arne
• Is Part Of: BMJ open. Volume 12:Issue 2(2022)
• Publication Date: 2022-02-01
• Subjects: health economics -- mental health -- sexual medicine; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-045980
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Living in an area with no or deficient structures for trans health care is disadvantageous for trans people. By providing an internet-based health care programme, i²TransHealth aims at reducing structural disadvantages for trans people living in areas lacking specialised care. The e-health intervention consists of video consultations and a 1:1 chat with a study therapist. Additionally, the i²TransHealth network cooperates with physicians, who especially offer crisis intervention close to the participants' place of residence. The aim of this study is to evaluate the (cost-)effectiveness of the internet-based health care programme for trans people compared with a control (waiting) group. The following research questions will be examined with a sample of 163 trans people: Does a 4-month treatment with the i²TransHealth internet-based health care programme improve patient-reported health-outcomes? Is i²TransHealth cost-effective compared with standard care from a societal or health care payers' perspective? Does the participation in and support by i²TransHealth lead to an increase of trans-related expertise in the physician network? Methods and analysis: In a randomised controlled trial, the outcomes of an internet-based health care programme for trans people will be investigated. In the intervention group, participants are invited to use i²TransHealth for 4 months. Participants allocated to the control group will be able to start with their transition-related care after 4 months of study participation. The primary outcome measure is defined as the reduction of psychosomatic symptoms, as assessed by the Brief Symptom Inventory-18, 4 months after using the i²TransHealth programme. Participants in both groups will undergo an assessment at baseline and 4 months after using i²TransHealth. Ethics and dissemination: Positive ethical approval was obtained from the Hamburg Medical Association (PV7131). The results will be disseminated to service users and their families via media, to health care professionals via professional training and meetings and to researchers via conferences and publications. Trial registration number: NCT04290286 . Protocol version: 22 December 2021 (V.1.0)